• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Myriad Genetics, Inc. - Common Stock (NQ:MYGN)

    8.180 +0.140 (+1.74%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 3, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Myriad Genetics, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 Next >
    Myriad Genetics’s (NASDAQ:MYGN) Q3 Earnings Results: Revenue In Line With Expectations But Stock Drops
    Genetic testing company Myriad Genetics (NASDAQ:MYGN) met Wall Streets revenue expectations in Q3 CY2025, but sales fell by 3.6% year on year to $205.7 million. The company’s outlook for the full year... 
    Via StockStory
    Earnings Scheduled For November 3, 2025
     
    Via Benzinga
    What To Expect From Myriad Genetics’s (MYGN) Q3 Earnings
    Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be reporting results this Monday after the bell. Here’s what to expect. 
    Via StockStory
    Exploring Myriad Genetics's Earnings Expectations
     
    Via Benzinga
    1 Stock Under $10 Worth Your Attention and 2 Facing Challenges
    Stocks under $10 pique our interest because they have room to grow (as well as the most affordable option contract premiums). That doesn’t mean they’re bargains though, and we urge investors to be... 
    Via StockStory
    2 Unpopular Stocks That Deserve a Second Chance and 1 That Underwhelm
    Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can... 
    Via StockStory
    3 Cash-Burning Stocks with Open Questions
    While some companies burn cash to fuel expansion, others struggle to turn spending into sustainable growth. A high cash burn rate without a strong balance sheet can leave investors exposed to... 
    Via StockStory
    Myriad Genetics, Omnicell, Globus Medical, Repligen, and Teleflex Stocks Trade Down, What You Need To Know
    A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump. 
    Via StockStory
    Topics Economy Government World Trade
    A Look Back at Therapeutics Stocks’ Q2 Earnings: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Pack
    Looking back on therapeutics stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Myriad Genetics (NASDAQ:MYGN) and its peers. 
    Via StockStory
    Topics Artificial Intelligence
    3 Unprofitable Stocks That Fall Short
    Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth. 
    Via StockStory
    3 Small-Cap Stocks That Concern Us
    Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside... 
    Via StockStory
    Firing on All Cylinders: Biogen (NASDAQ:BIIB) Q2 Earnings Lead the Way
    The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q2, starting with Biogen... 
    Via StockStory
    Topics Artificial Intelligence
    1 Momentum Stock for Long-Term Investors and 2 Facing Challenges
    The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro... 
    Via StockStory
    3 Russell 2000 Stocks with Open Questions
    The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the... 
    Via StockStory
    Topics Regulatory Compliance
    3 Stocks Under $10 We Approach with Caution
    Stocks under $10 pique our interest because they have room to grow (as well as the most affordable option contract premiums). That doesn’t mean they’re bargains though, and we urge investors to be... 
    Via StockStory
    Opendoor, SmartRent, Myriad Genetics, Reddit, and Unity Stocks Trade Down, What You Need To Know
    A number of stocks fell in the afternoon session after the major indices continued to pull back, with technology stocks accounting for most of the market's largest decliners. A key reason for this... 
    Via StockStory
    Topics Artificial Intelligence Economy World Trade
    3 Healthcare Stocks We’re Skeptical Of
    Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, and over the past six... 
    Via StockStory
    Topics Stocks
    MYGN Q2 Deep Dive: Oncology Strategy Shift and Product Execution Shape Guidance
    Genetic testing company Myriad Genetics (NASDAQ:MYGN) reported Q2 CY2025 results beating Wall Street’s revenue expectations, but sales were flat year on year at $213.1 million. The company’s full-year... 
    Via StockStory
    Topics Artificial Intelligence
    What's going on in today's session
    Looking for insights into the US markets one hour before the close of the markets on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
    Via Chartmill
    Why Is Myriad Genetics (MYGN) Stock Soaring Today
    Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 36.4% in the afternoon session after the company reported strong second-quarter earnings that surpassed analyst expectations and... 
    Via StockStory
    Topics Artificial Intelligence
    12 Health Care Stocks Moving In Wednesday's Intraday Session
     
    Via Benzinga
    Here are the top movers in Wednesday's session.
    Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report. 
    Via Chartmill
    Shopify, Astera Labs, Myriad Genetics, Grocery Outlet And Other Big Stocks Moving Higher On Wednesday
     
    Via Benzinga
    The market is filled with gapping stocks in Wednesday's session.
    Traders are paying attention to the gapping stocks in Wednesday's session. Let's dive into which stocks are experiencing notable gaps. 
    Via Chartmill
    Discover the top movers in Wednesday's pre-market session.
    The US market session of Wednesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today. 
    Via Chartmill
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
     
    Via Benzinga
    Stock Market Today: US Futures Edge Higher As Investors Await Earnings From McDonald's, Uber And Walt Disney
    US stock futures rose on Wed. after falling on Thurs. Trump threatened tariffs on imported pharma up to 250%. Bond yields down & Fed may cut rates. 
    Via Benzinga
    Topics Economy Government World Trade
    Why Astera Labs Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket
     
    Via Benzinga
    Myriad Genetics Surges 35.67% After Hours Following Strong Q2 Earnings Beat, Raised Revenue Guidance
    After posting second-quarter results that beat revenue and EPS estimates and raising its 2025 guidance, Myriad Genetics jumped 35.66% to $5.25 after-hours on Tuesday. 
    Via Benzinga
    Topics Earnings
    Myriad Genetics (MYGN) Q2 Revenue Up 6%
    Via The Motley Fool
    < Previous 1 2 3 4 5 6 7 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.